Aslan Total Debt Trend from 2010 to 2021

ASLN -  USA Stock  

USD 1.30  0.14  9.72%

Aslan Pharmaceuticals Total Debt yearly trend continues to be quite stable with very little volatility. The value of Total Debt is projected to decrease to about 18.2 M. From the period between 2010 and 2021, Aslan Pharmaceuticals, Total Debt regression line of its data series had standard deviation of 4,632,283 and standard deviation of  4,632,283. Aslan Pharmaceuticals Operating Expenses is quite stable at the moment as compared to the past year. The company's current value of Operating Expenses is estimated at 16.92 Million. Research and Development Expense is expected to rise to about 13.4 M this year, although the value of Consolidated Income will most likely fall to (19.1 M).

Aslan Historical Trends 

 
Refresh
Check Aslan Pharmaceuticals financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Aslan main balance sheet or income statement drivers, such as Cost of Revenue of 400.6 K, Gross Profit of 2.4 M or Interest Expense of 1.1 M, as well as many exotic indicators such as Asset Turnover of 0.0707, Current Ratio of 1.49 or Gross Margin of 0.8. Aslan financial statements analysis is a perfect complement when working with Aslan Pharmaceuticals Valuation or Volatility modules. It can also supplement various Aslan Pharmaceuticals Technical models. Please continue to the analysis of Aslan Pharmaceuticals Correlation against competitors.

Aslan Pharmaceuticals Quarterly Total Debt

31.16 MillionShare

Aslan Total Debt Breakdown

Showing smoothed Total Debt of Aslan Pharmaceuticals with missing and latest data points interpolated. Total Debt of Aslan Pharmaceuticals is a combination of both Aslan Pharmaceuticals short-term and long-term liabilities. Short-term debts are those that must be paid back within a year. This type of debt applies to things like lines of credit or short-term term bonds. Long-term debt of Aslan Pharmaceuticals includes liability that must be paid off in more than a year. This typically includes large senior debts like mortgages, bonds, as well as business loans or leases. A component of Total Liabilities representing the total amount of current and non-current debt owed. Includes secured and unsecured bonds issued; commercial paper; notes payable; credit facilities; lines of credit; capital lease obligations; operating lease obligations; and convertible notes.Aslan Pharmaceuticals' Total Debt historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Aslan Pharmaceuticals' overall financial position and show how it may be relating to other accounts over time.
ViewLast Reported 15.54 M10 Years Trend
Increasing
Slightly volatile
 Total Debt 
Share
      Timeline 

Aslan Total Debt Regression Statistics

Arithmetic Mean 11,511,267
Geometric Mean 10,784,691
Coefficient Of Variation 40.24
Mean Deviation 4,010,212
Median 8,335,631
Standard Deviation 4,632,283
Range 10,919,446
R-Value 0.85
R-Squared 0.72
Significance 0.00049581
Slope 1,089,179

Aslan Total Debt History

20179.7 M
201814 M
201918.6 M
202019.3 M
202118.2 M

Other Fundumenentals of Aslan Pharmaceuticals

Aslan Pharmaceuticals Total Debt component correlations

About Aslan Pharmaceuticals Financial Statements

There are typically three primary documents that fall into the category of financial statements. These documents include Aslan Pharmaceuticals income statement, its balance sheet, and the statement of cash flows. Aslan Pharmaceuticals investors use historical funamental indicators, such as Aslan Pharmaceuticals's Total Debt, to determine how well the company is positioned to perform in the future. Although Aslan Pharmaceuticals investors may use each financial statement separately, they are all related. The changes in Aslan Pharmaceuticals's assets and liabilities, for example, are also reflected in the revenues and expenses that we see on Aslan Pharmaceuticals's income statement, which results in the company's gains or losses. Cash flows can provide more information regarding cash listed on a balance sheet, but not equivalent to net income shown on the income statement. We offer a historical overview of the basic patterns found on Aslan Pharmaceuticals Financial Statements. Understanding these patterns can help to make the right decision on long term investment in Aslan Pharmaceuticals. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for 2021
Total Debt19.3 M18.2 M
ASLAN Pharmaceuticals Limited, a clinical-stage immunology focused biopharmaceutical company, engages in developing various treatments to transform the lives of patients. The company was founded in 2010 and is headquartered in Singapore. Aslan Pharmaceuticals operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 18 people.

Aslan Pharmaceuticals Investors Sentiment

The influence of Aslan Pharmaceuticals' investor sentiment on the probability of its price appreciation or decline could be a good factor in your decision-making process regarding taking a position in Aslan. The overall investor sentiment generally increases the direction of a stock movement in a one-year investment horizon. However, the impact of investor sentiment on the entire stock markets does not have a solid backing from leading economists and market statisticians.

Aslan Pharmaceuticals Implied Volatility

    
  192.33  
Aslan Pharmaceuticals' implied volatility exposes the market's sentiment of Aslan Pharmaceuticals stock's possible movements over time. However, it does not forecast the overall direction of its price. In a nutshell, if Aslan Pharmaceuticals' implied volatility is high, the market thinks the stock has potential for high price swings in either direction. On the other hand, the low implied volatility suggests that Aslan Pharmaceuticals stock will not fluctuate a lot when Aslan Pharmaceuticals' options are near their expiration.
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards Aslan Pharmaceuticals in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, Aslan Pharmaceuticals' short interest history, or implied volatility extrapolated from Aslan Pharmaceuticals options trading.

Current Sentiment - ASLN

Aslan Pharmaceuticals Investor Sentiment

Macroaxis portfolio users are unresponsive in their sentiment towards investing in Aslan Pharmaceuticals. What is your sentiment towards investing in Aslan Pharmaceuticals? Are you bullish or bearish?
Bullish
Bearish
50% Bullish
50% Bearish
Skip

Pair Trading with Aslan Pharmaceuticals

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Aslan Pharmaceuticals position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Aslan Pharmaceuticals will appreciate offsetting losses from the drop in the long position's value.

Aslan Pharmaceuticals Pair Correlation

Equities Pair Trading Analysis

Correlation analysis and pair trading evaluation for Aslan Pharmaceuticals and Bioatla. Pair trading can be used as a hedging technique within a particular sector or industry or even over random equities to generate better risk-adjusted return
Run Pair Correlation  
Please continue to the analysis of Aslan Pharmaceuticals Correlation against competitors. Note that the Aslan Pharmaceuticals information on this page should be used as a complementary analysis to other Aslan Pharmaceuticals' statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try Price Exposure Probability module to analyze equity upside and downside potential for a given time horizon across multiple markets.

Complementary Tools for Aslan Stock analysis

When running Aslan Pharmaceuticals price analysis, check to measure Aslan Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Aslan Pharmaceuticals is operating at the current time. Most of Aslan Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Aslan Pharmaceuticals' future price movements. You can analyze the entity against its peers and financial market as a whole to determine factors that move Aslan Pharmaceuticals' price. Additionally, you may evaluate how the addition of Aslan Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.
Technical Analysis
Check basic technical indicators and analysis based on most latest market data
Go
Stock Screener
Find equities using custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook.
Go
Portfolio Comparator
Compare the composition, asset allocations and performance of any two portfolios in your account
Go
Cryptocurrency Center
Build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency
Go
ETF Directory
Find actively traded Exchange Traded Funds (ETF) from around the world
Go
Fundamental Analysis
View fundamental data based on most recent published financial statements
Go
Portfolio Center
All portfolio management and optimization tools to improve performance of your portfolios
Go
Correlation Analysis
Reduce portfolio risk simply by holding instruments which are not perfectly correlated
Go
Portfolio Anywhere
Track or share privately all of your investments from the convenience of any device
Go
Transaction History
View history of all your transactions and understand their impact on performance
Go
Is Aslan Pharmaceuticals' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Aslan Pharmaceuticals. If investors know Aslan will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Aslan Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Aslan Pharmaceuticals is measured differently than its book value, which is the value of Aslan that is recorded on the company's balance sheet. Investors also form their own opinion of Aslan Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Aslan Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Aslan Pharmaceuticals' market value can be influenced by many factors that don't directly affect Aslan Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Aslan Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine Aslan Pharmaceuticals value by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Aslan Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.